Cardiometabolic comorbidity

Overview

Cardiometabolic comorbidity refers to the coexistence of metabolic abnormalities and cardiovascular disease risk or established cardiovascular pathology in the same individual. In the recent literature provided, this concept is most closely reflected by metabolic syndrome (MetS) and related cardiometabolic burden, including obesity, arterial hypertension, coronary artery disease, venous thromboembolism, and broader cardiovascular-kidney-metabolic (CKM) risk. It is not a single disease mechanism, but rather a clinical state in which obesity, insulin resistance, dyslipidemia, elevated Blood Pressure, and chronic low-grade inflammation converge to increase cardiovascular morbidity and mortality.

Biologically, cardiometabolic comorbidity is shaped by interacting pathways involving adiposity, inflammatory signaling, the renin–angiotensin system, mitochondrial dysfunction, and ectopic fat accumulation in organs such as the liver and vasculature. Recent studies also place this burden in the context of metabolic dysfunction–associated steatotic liver disease, psoriasis, polycystic ovary syndrome, diabetes, and antipsychotic exposure, emphasizing that cardiometabolic risk often emerges across multiple chronic conditions rather than in isolation.

Focus of Latest Publications

Recent publications have examined cardiometabolic comorbidity primarily through the lens of metabolic syndrome and its overlap with other chronic conditions and risk factors. Several studies used cross-sectional designs to assess how occupational sedentary behavior, nutritional status, and disease-specific populations relate to metabolic syndrome and related cardiometabolic outcomes. One study highlighted the scarcity of evidence linking prolonged occupational sedentary behavior with metabolic syndrome and related diseases in male workers, while another evaluated alpha-tocopherol intake and blood status in relation to metabolic syndrome and its components in two Hispanic/Latino populations, finding population-specific associations.

Other reports focused on groups with elevated cardiometabolic risk. In women with polycystic ovary syndrome in western Algeria, investigators assessed the prevalence and clinical, hormonal, and metabolic correlates of metabolic syndrome. Among survivors of pediatric hematopoietic stem cell transplantation for hematological malignancy, a protocol was presented to estimate the burden of metabolic syndrome, vascular damage, and accelerated aging, reflecting concern about long-term metabolic and cardiovascular disease after childhood cancer treatment. A retrospective study of guttate psoriasis also explored systemic comorbidities, reporting metabolic syndrome in a subset of patients and noting a possible association with recurrence patterns.

Pregnancy-related metabolic risk was another recurring theme. One study evaluated whether a Mediterranean-based nutritional intervention during pregnancy influenced the prevalence of metabolic syndrome six years postpartum and whether postpartum lifestyle behaviors predicted prevention. The abstract emphasizes pre-pregnancy body mass index and gestational diabetes as key determinants of long-term metabolic risk. Together, these publications underscore the multifactorial nature of cardiometabolic comorbidity and the importance of behavioral, nutritional, reproductive, and disease-specific factors in shaping metabolic syndrome and related outcomes.